Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date

3220 results found

2023 ∙ Kuniduzi, Y. Chen, B. Zeng, J. Sun, X. Chen, T. Qian, X. Wang, J. Liang, F. Abuduxukuer, R. Yusufu, M. Xu, S. Zhang, X.

Efficacy and safety of a fourth dose of the COVID-19 vaccine in kidney transplant recipients: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Taheri, S.

Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Joudeh, A. I. Lutf, A. Q. Mahdi, S. Tran, G.

Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review

  • Adolescents
  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Conti, A. Broglia, G. Sacchi, C. Risi, F. Barone-Adesi, F. Panella, M.

Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis

  • Children
  • Adolescents
  • Adults
  • Meningococcal disease
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Ma, J. Chen, L. Tang, S. Shi, Y.

Efficacy and safety of respiratory syncytial virus vaccination during pregnancy to prevent lower respiratory tract illness in newborns and infants: a systematic review and meta-analysis of randomized controlled trials

  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2023 ∙ Zeevaert, R. Thiry, N. Maertens de Noordhout, C. Roberfroid, D.

Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis

  • Adults
  • Older adults
  • Herpes zoster
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Ibrahim Khalil, Ahmadaye Zhang, Li Muwonge, Richard Sauvaget, Catherine Basu, Partha

Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials

  • All age groups
  • Human papillomavirus (HPV)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Wen, J. Liu, Q. Tang, D. He, J. Q.

Efficacy of BCG Vaccination against COVID-19: Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Dou, D. Zhang, F. Deng, X. Ma, Y. Wang, S. Ji, X. Zhu, X. Wang, D. Zhang, S. Zhao, L.

Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Meo, S. A. Aftab, S. Bayoumy, N. M. Meo, A. S.

Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...